来那度胺与地塞米松联合诱导可增加既往未经治疗的多发性骨髓瘤患者的调节性细胞。 - Suppr

Suppr

超能文献

Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma.

作者信息

Muthu Raja Karthick Raja, Kovarova Lucie, Hajek Roman

出版信息

Leuk Lymphoma. 2012 Jul;53(7):1406-8. doi: 10.3109/10428194.2011.652106. Epub 2012 Jan 31.

DOI:10.3109/10428194.2011.652106

PMID:22200079

Abstract

摘要

相似文献

Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma.来那度胺与地塞米松联合诱导可增加既往未经治疗的多发性骨髓瘤患者的调节性细胞。

Leuk Lymphoma. 2012 Jul;53(7):1406-8. doi: 10.3109/10428194.2011.652106. Epub 2012 Jan 31.

Multiple myeloma and immunomodulation: regulating the regulatory cells.多发性骨髓瘤与免疫调节：调控调节性细胞

Leuk Lymphoma. 2012 Jul;53(7):1253-4. doi: 10.3109/10428194.2012.670233. Epub 2012 Apr 3.

Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells.来那度胺单药或与地塞米松联合使用，对异基因干细胞移植后复发的多发性骨髓瘤患者具有高效性，并能增加CD4+Foxp3+ T细胞的频率。

Leukemia. 2009 Mar;23(3):605-7. doi: 10.1038/leu.2008.247. Epub 2008 Sep 11.

Efficacy of thalidomide-based therapy following lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.来那度胺联合地塞米松治疗后复发/难治性多发性骨髓瘤患者使用沙利度胺为基础的治疗的疗效

Am J Hematol. 2013 Apr;88(4):337-8. doi: 10.1002/ajh.23394. Epub 2013 Mar 12.

Flow cytometry-based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment.基于流式细胞术对来那度胺联合地塞米松治疗前后多发性骨髓瘤患者CD8调节性T细胞的计数及功能特征分析

Cytometry B Clin Cytom. 2014 Jul;86(4):220-8. doi: 10.1002/cyto.b.21109. Epub 2013 Aug 6.

Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.新诊断多发性骨髓瘤患者中同步沙利度胺、来那度胺和每周地塞米松的 II 期试验。

Clin Lymphoma Myeloma Leuk. 2012 Jun;12(3):186-90. doi: 10.1016/j.clml.2012.01.004. Epub 2012 Feb 28.

Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome.硼替佐米或来那度胺联合地塞米松治疗多发性骨髓瘤患者调节性 T 细胞（Tregs）改变的评估：与治疗结果的相关性。

Ann Hematol. 2019 Jun;98(6):1457-1466. doi: 10.1007/s00277-019-03657-3. Epub 2019 Mar 20.

Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma.来那度胺联合地塞米松治疗 75 岁以上复发多发性骨髓瘤患者的疗效。

Leuk Lymphoma. 2012 Jul;53(7):1318-20. doi: 10.3109/10428194.2011.654116. Epub 2012 Jan 31.

Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.苯达莫司汀-来那度胺-地塞米松及苯达莫司汀-硼替佐米-地塞米松联合方案用于晚期多发性骨髓瘤的活性及毒性特征

Leuk Lymphoma. 2014 May;55(5):1191-3. doi: 10.3109/10428194.2013.820289. Epub 2013 Aug 13.

Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma.泊马度胺、地塞米松和达雷妥尤单抗治疗复发/难治性多发性骨髓瘤患者的免疫调节作用。

Clin Cancer Res. 2020 Nov 15;26(22):5895-5902. doi: 10.1158/1078-0432.CCR-20-1781. Epub 2020 Sep 14.

引用本文的文献

Tregs at Diagnosis as a Potential Biomarker for Predicting High-Risk Functionality in Newly Diagnosed Multiple Myeloma.诊断时的调节性T细胞作为预测新诊断多发性骨髓瘤高风险功能的潜在生物标志物。

Cancer Med. 2025 Jun;14(11):e70980. doi: 10.1002/cam4.70980.

Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment.骨髓微环境中的多发性骨髓瘤治疗。

Curr Oncol. 2022 Nov 21;29(11):8975-9005. doi: 10.3390/curroncol29110705.

Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft-versus-host disease by inhibiting T-cell migration to the gastrointestinal tract.异基因造血干细胞移植后早期给予来那度胺可通过抑制 T 细胞向胃肠道迁移来抑制移植物抗宿主病。

Immun Inflamm Dis. 2022 Sep;10(9):e688. doi: 10.1002/iid3.688.

Absolute Lymphocyte Counts After Lenalidomide Initiation may Predict the Prognosis of Patients With Relapsed or Refractory Multiple Myeloma.来那度胺起始治疗后的绝对淋巴细胞计数可能预测复发或难治性多发性骨髓瘤患者的预后。

Cancer Diagn Progn. 2021 Jul 3;1(3):221-229. doi: 10.21873/cdp.10030. eCollection 2021 Jul-Aug.

Regulatory T-Cells and Multiple Myeloma: Implications in Tumor Immune Biology and Treatment.调节性T细胞与多发性骨髓瘤：对肿瘤免疫生物学及治疗的影响

J Clin Med. 2021 Oct 5;10(19):4588. doi: 10.3390/jcm10194588.

Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies.单核细胞来源的髓系抑制细胞在血液系统恶性肿瘤中的作用。

Int J Mol Sci. 2019 Nov 1;20(21):5459. doi: 10.3390/ijms20215459.

Lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccine.来那度胺可提高基于干扰素-α-树突状细胞的淋巴瘤疫苗的治疗效果。

Cancer Immunol Immunother. 2019 Nov;68(11):1791-1804. doi: 10.1007/s00262-019-02411-y. Epub 2019 Oct 16.

Context-Dependent Effect of Glucocorticoids on the Proliferation, Differentiation, and Apoptosis of Regulatory T Cells: A Review of the Empirical Evidence and Clinical Applications.糖皮质激素对调节性 T 细胞增殖、分化和凋亡的影响：基于实证证据和临床应用的综述

Int J Mol Sci. 2019 Mar 6;20(5):1142. doi: 10.3390/ijms20051142.

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients.来那度胺联合低剂量环磷酰胺和泼尼松可调节淋巴细胞中的IKAROS和AIOLOS，从而对来那度胺难治性多发性骨髓瘤患者产生免疫刺激作用。

Oncotarget. 2018 Sep 21;9(74):34009-34021. doi: 10.18632/oncotarget.26131.

Circulating Regulatory T-Cells in Monoclonal Gammopathies of Uncertain Significance and Multiple Myeloma: In Search of a Role.循环调节性 T 细胞在意义未明的单克隆丙种球蛋白病和多发性骨髓瘤中的作用：探索其作用。

J Immunol Res. 2016;2016:9271469. doi: 10.1155/2016/9271469. Epub 2016 Jul 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验